Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Qlucore Receives European Funding That will Benefit Personalized Medicine

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Hepatitis C patients to benefit from European funding awarded to Qlucore.

Qlucore has been awarded funding of €0.6 million over a three year period by the European Commission's 7th Framework Programme as part of a €6.0 million consortium project (Grant n° 601851) for the development of mathematical and statistical algorithms focusing on integrating data from multiple analytical platforms focusing on integrating genetic and proteomic data with clinical variables.

On receiving the award, Carl-Johan Ivarsson, CEO, Qlucore said, "Personalized medicine, and in particular Hepatitis C patients, will benefit from the project outcome. One of the primary objectives of the consortium is to provide predictive tests that will lead to improvements in the health of these patients, which will simultaneously reduce the costs of medical treatment."

The consortium, known as the PoC-HCV consortium, aims to develop integrated genetic and protein biomarker tests for use in treating and monitoring HCV patients, as well as in clinical research.

Data and algorithms will be tailored for analysis and treatment in a Point of Care environment for Hepatitis C. One of the outputs from the consortium will be a mobile application prototype where the algorithms are implemented.

Establishing a path for validation and implementation of point-of-care medical devices is a challenge, and the driving vision of the Consortium.

The consortium additionally consists of the coordinator Inserm (Institut Pasteur) (France), Inserm Transfert (France), Epistem (UK) and Biosurfit (Portugal).

With the primary objective to provide Point of Care diagnostic and predictive tests and reduce costs, the approach will capitalize on the consortium's combined expertise spanning leading edge miniaturized molecular testing, lab-on-a-chip systems and algorithm design.

These enabling technologies will permit the development and delivery of the first integrated genetic and protein biomarker tests, applied here to Hepatitis C disease for: (i) making the decision to treat; (ii) selection of therapy; (iii) response-guided monitoring; and (iv) clinical research practices.

Hepatatis-C is a global public health problem with over 150 million people infected worldwide, representing a 15 billion Euro/year market. It is particularly prevalent in under-developed countries and treatments can be very costly.

One vision is to allow the physicians to make better treatment decisions (selecting the correct drug) and hence lower the total cost of treatment. In countries with many infected patients and limited healthcare budget this will provide an enormous improvement in quality of life for this patient group.

The algorithms developed by Qlucore will be based on classification techniques. They will also be available in future versions of Qlucore Omics Explorer and hence enable researchers and physicians in other areas to benefit from the results.

Qlucore has recruited and increased its engineering capacity in order to fulfil its role in the PoC HCV consortium. This, combined with the recently announced grant to Qlucore from VINNOVA (Swedish Governmental Agency for Innovation Systems) is additional validation of the high value being placed on developments currently being undertaken by Qlucore.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Revealing Human-growth Patterns in Transcriptomic Data
Understanding how children grow is key to understanding many childhood diseases and conditions, particularly those affecting growth.
Monday, May 19, 2014
Qlucore, Nebion Collaborate
Partnership aims to address complementary use cases.
Friday, February 07, 2014
Using Qlucore Omics Explorer for Interpreting Leukemia Proteomics Data
Qlucore software has speeded up the process and enabled discovery for leukemia researcher Steven Kornblau.
Monday, November 18, 2013
Researchers Develop Animal Free Methods for Testing Chemical Compounds for Allergens
EU-funded research project developing in vitro (‘out of body’) test strategies to reduce or replace animal testing use gene expression analysis software.
Monday, April 08, 2013
New Biomarkers Could Offer Vital Clues for Cancer Research
European funding for cancer research has led to some interesting results in recent years, says Carl-Johan Ivarsson, CEO at Qlucore.
Friday, May 04, 2012
Unlocking the Secrets of Complex Genetic Data
A new approach to data analysis is helping researchers at Cincinnati Children's Hospital Medical Center to unravel the mysteries of human disease, says Carl-Johan Ivarsson, President of Qlucore.
Monday, March 19, 2012
Scientific News
Genes That Protect African Children From Developing Malaria Identified
Variations in DNA at a specific location on the genome that protect African children from developing severe malaria, in some cases nearly halving a child’s chance of developing the life-threatening disease, have been identified in the largest genetic association study of malaria to date.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
Dormant Viral Genes May Awaken to Cause ALS
NIH human and mouse study may open an unexplored path for finding treatments.
Scientists Create World’s Largest Catalog of Human Genomic Variation
An international team of scientists from the 1000 Genomes Project Consortium has created the world’s largest catalog of genomic differences among humans, providing researchers with powerful clues to help them establish why some people are susceptible to various diseases.
Five Genetic Regions Implicated In Cystic Fibrosis Severity
An international consortium of researchers conducted the largest-ever CF genome-wide analysis to find new therapeutic targets.
Greater Understanding Of Polycystic Ovary Syndrome
A new genetic study of over 200,000 women reveals the underlying mechanisms of polycystic ovary syndrome, as well as potential interventions.
New Autism Genes Are Revealed in Largest-Ever Study
Work draws more detailed picture of genetic risk, sheds light on sex differences in diagnosis.
A Fundamental Protection Mechanism Against Formalin In Mammals is Revealed
Formaldehyde, or formalin, is well known to all of us as a common chemical used in many industrial processes and also as a preservative, remarkably we also produce formaldehyde in our bodies.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Genetic Adaptations to Diet and Climate
Researchers found genetic variations in the Inuit of Greenland that reflect adaptations to their specific diet and climate.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos